Back to Journals » Journal of Pain Research » Volume 6
Efficacy of methylprednisolone versus other pharmacologic interventions for the treatment of central post-stroke pain: a retrospective analysis
Authors Pellicane AJ, Millis SR
Received 10 April 2013
Accepted for publication 1 June 2013
Published 18 July 2013 Volume 2013:6 Pages 557—563
DOI https://doi.org/10.2147/JPR.S46530
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Anthony J Pellicane, Scott R Millis
Department of Physical Medicine and Rehabilitation, Wayne State University School of Medicine, Rehabilitation Institute of Michigan in the Detroit Medical Center, Detroit, MI, USA
Purpose: To determine if an oral, tapered methylprednisolone regimen is superior to other commonly used pharmacologic interventions for the treatment of central post-stroke pain (CPSP).
Patients and methods: In this study, the charts of 146 stroke patients admitted to acute inpatient rehabilitation were retrospectively reviewed. Patients diagnosed with CPSP underwent further chart review to assess numerical rating scale for pain scores and as-needed pain medication usage at different time points comparing CPSP patients treated with methylprednisolone to those treated with other pharmacologic interventions.
Results: In the sample, 8.2% were diagnosed with CPSP during acute care or inpatient rehabilitation. Mean numerical rating scale for pain scores day of symptom onset did not differ between those patients treated with methylprednisolone versus those treated with other pharmacologic interventions (mean ± standard deviation; 6.1 ± 2.3 versus 5.7 ± 1.6, P = 0.77). However, mean numerical rating scale for pain scores differed significantly 1-day after treatment initiation (1.7 ± 2.1 versus 5.0 ± 1.9, P = 0.03) and 1-day prior to rehabilitation discharge (0.3 ± 0.9 versus 4.1 ± 3.2, P = 0.01) between the two groups. Compared to day of symptom onset, as-needed pain medication usage within the methylprednisolone group was marginally less 1-day after treatment initiation (Z = -1.73, P = 0.08) and 1-day prior to rehabilitation discharge (Z = -1.89, P = 0.06). No difference in as-needed pain medication usage existed within the non-steroid group at the same time points.
Conclusion: Methylprednisolone is a potential therapeutic option for CPSP. The findings herein warrant study in prospective trials.
Keywords: stroke, pain, central post-stroke pain, complex regional pain syndromes, therapeutics, neuralgia
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.